Liraglutide ameliorates TAC-induced cardiac hypertrophy and heart failure by upregulating expression level of ANP expression

• DOI: 10.1016/j.heliyon.2024.e32229
• Publication Date: 2024-05-31T11:51:18Z
• Authors: Ruisha Li; Keyin Zhang; Zhenjun Xu; Yanrong Yu; Dongjin Wang; Kai Li; Wenxue Liu; Jun Pan
• Keywords: Cardiac Fibrosis

Recent studies have underscored the cardioprotective properties of liraglutide. This research explores its impact on cardiac hypertrophy and heart failure following transverse aortic constriction (TAC). We found that liraglutide administration markedly ameliorated hypertrophy, fibrosis, function. These benefits correlated with increased ANP expression reduced activity in calcineurin A/NFATc3 signaling pathway. Moreover, mitigated ER stress cardiomyocyte apoptosis, enhanced autophagy. Notably, positive effects diminished when co-administered A71915, an inhibitor, suggesting upregulation is critical to mechanism.